# An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

> **NCT02623699** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 176 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Tofersen
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02623699
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-20
- **Primary completion:** 2021-07-16
- **Final completion:** 2021-07-16
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2023-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02623699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02623699, "An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02623699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*